Obstructive sleep apnea (OSA) is a common, devastating and costly condition. It affects an estimated 100 million people worldwide, of whom 18 million are in the US alone, and its societal costs are huge. A 2010 joint Harvard Medical School-McKinsey & Company report estimated that the annual cost of moderate to severe OSA in the US is between $65bn- $165bn, including diagnosis and treatment, hidden health-care costs (notably cardiovascular disease, with which moderate to severe OSA is strongly associated), traffic and workplace accidents, and absenteeism.
For decades, the go-to treatment for moderate to severe sleep apnea has been for the patient to wear a continuous positive airway pressure (CPAP) device during sleep. (Market dominators for CPAP are ResMed Inc. and Philips Respironics.) These provide pressurized air on both inhalation and exhalation that keeps the airway open; it is highly effective, thus reducing the number of apneic episodes. But compliance is low
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?